Jae-hoon D. Lee

Busan, KR 
Busan, KR 

Overview

Jae-hoon Lee practices practicing medicine in Busan, Republic of Korea.

Their clinical expertise encompasses Bone Tumor, Pyogenic Granuloma, Nasopharyngeal Carcinoma, Laminectomy, and Endoscopy.

They are actively involved in clinical research, co-authoring 91 peer reviewed articles and participating in 3 clinical trials.

Locations

Busan, Republic of Korea
Other Locations
R&D Center, Wondu, Republic of Korea
Yongin, Republic of Korea
Seoul, Republic of Korea
Wanju, Republic of Korea
Puch'on, Republic of Korea
Department Of Otolaryngology Head And Neck Surgery, Iksan, Republic of Korea
Chinju, Republic of Korea
Cheonan, Republic of Korea
Pyeongtaek, Republic of Korea
Jungnam, Republic of Korea
Uijeongbu St. Mary's Hospital, Uijeongbu-si, Republic of Korea
Incheon, Republic of Korea
Geoje, 656710, Republic of Korea

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator Choice of BTK Inhibitor in Patients With Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN MCL-321)
Enrollment Status: Active_not_recruiting
Publish Date: May 15, 2026
Intervention Type: Drug
Study Drugs: LOXO-305, Ibrutinib, Acalabrutinib, Zanubrutinib
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
A Phase 3 Open-Label, Randomized Study of LOXO-305 Versus Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in BTK Inhibitor Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321)
Enrollment Status: Active_not_recruiting
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Idelalisib, Bendamustine, Rituximab
Study Phase: Phase 3
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
A Phase 3 Open-Label, Randomized Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab in Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Enrollment Status: Active_not_recruiting
Publish Date: January 22, 2026
Intervention Type: Drug
Study Drugs: Pirtobrutinib, Bendamustine, Rituximab
Study Phase: Phase 3
View 2 Less Clinical Trials

91 Total Publications

Optimization of Difluorophenazine-Based Polymers via Substituent Modifications for Solar Energy Applications.
Optimization of Difluorophenazine-Based Polymers via Substituent Modifications for Solar Energy Applications.
Journal: Materials (Basel, Switzerland)
Published: June 09, 2026

Frequently Asked Questions about Jae-hoon D. Lee

Is Jae-hoon D. Lee a top-rated expert for Bone Tumor?

MediFind is an objective health platform that identifies experts based on real-world data. Jae-hoon D. Lee is classified as an Experienced expert for Bone Tumor, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Jae-hoon D. Lee participate in research or clinical trials?

Yes. Jae-hoon D. Lee has published 91 articles and abstracts on conditions like Bone Tumor. You can view a list of Jae-hoon D. Lee's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Lee's expertise for a condition
ConditionClose
        View All 20 Experienced Conditions
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile